The results of this PMS in real-world clinical practice in Japan did not reveal any additional safety concerns compared with clinical trials of the combination treatment of encorafenib plus binimetinib in patients with BRAF-mutant malignant melanoma. The gene discussed is BRAF; the disease is melanoma.